Please assess the completion status of the following clinical trial:

Trial Title: Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 89 years old~* Patients undergoing primary anterior cruciate ligament (ACL) reconstruction surgery~Exclusion Criteria:~* Patients below age 18 or above age 89~* Illiterate or non-English speaking individuals~* Patients with contraindications to Ketorolac~* History of chronic alcohol or drug abuse~* Chronic use of psychotropic or analgesic drugs~* Known peptic ulcer disease or bleeding diasthesis~* Renal dysfunction (estimated glomerular filtration rate \< 50 mL/min/1.73m2)~* Breastfeeding women~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: EXPERIMENTAL): Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
- Ketorolac (Type: EXPERIMENTAL): Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control

Based on this trial design, predict the completion outcome and termination type (if applicable).